Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Importation Sinks In Senate, But Leaves Anticounterfeiting Regs In Its Wake

Executive Summary

Although the drug importation provisions included in the Senate's version of the FDA Revitalization Act are not expected to create a cross-border trading system, their anticounterfeiting language could still have a significant impact on industry

You may also be interested in...



Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

e-Pedigree Requirement In Calif. Sets High Hurdle; Pfizer Wants 5 More Years

The Jan. 1, 2009 deadline set by the California Board of Pharmacy mandating the establishment of an e-pedigree system is coming under pressure, with industry telling the state that the requirement of "item-level serialization" is not a realistic goal

Related Content

UsernamePublicRestriction

Register

PS048365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel